All In Biotech

BLA 761100 · Samsung Bioepis CO LTD

Ontruzant

Trastuzumab-Dttb · Iv (Infusion) · HER2/neu Receptor Antagonist

Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jan 18, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,500

287 Phase 3, 274 recruiting

FAERS reports

32,364

30,693 serious, 3,644 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY See full prescribing information for complete boxed warning Cardiomyopathy: trastuzumab products can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue Ontruzant for cardiomyopathy. ( 2.5 , 5.1 ) Infusion Reactions, Pulmonary Toxicity: Discontinue Ontruzant for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. ( 5.2 , 5.4 ) Embryo-Fetal Toxicity: Exposure to trastuzumab products during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal...

What it is approved for

From the label in effect Apr 20, 2026.

Ontruzant is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.2 ). 1.1 Adjuvant Breast Cancer Ontruzant is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ] . 1.2 Metastatic Breast Cancer Ontruzant is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product [see Dosage and Administration (2.2) ] . 1.3 Metastatic Gastric Cancer Ontruzant is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an...

Mechanism: The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Trastuzumab products have been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Trastuzumab products are mediators of antibody-dependent cellular cytotoxicity (ADCC). In vitro , trastuzumab product-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ONTRUZANT · TRASTUZUMAB-DTTB 150MG · POWDER, IV (INFUSION) · Prescription
  • ONTRUZANT · TRASTUZUMAB-DTTB 420MG · POWDER, IV (INFUSION) · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Trastuzumab" as an intervention, any sponsor and status, largest first.

All 1,500 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea3,735
  • off label use3,004
  • nausea2,550
  • fatigue2,211
  • myelosuppression1,886
  • vomiting1,743
  • disease progression1,698
  • neutropenia1,608
  • dyspnoea1,388
  • pyrexia1,367
  • anaemia1,311
  • neuropathy peripheral1,225

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200425
200539
200613
200780
2008152
2009312
2010444
2011393
2012699
2013841
2014712
2015856
2016810
2017883
20181,716
20192,305
20202,678
20213,141
20223,181
20233,217
20244,185
20253,333
20262,349

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ontruzant (Trastuzumab-Dttb)

2024 spending

$3.8M

Beneficiaries

129

889 claims

Per beneficiary

$29,808

$1,965.89 per unit

View as table
YearSpending
2020$0
2021$0
2022$963,319
2023$1,665,004
2024$3,845,262

Part B: Ontruzant (Trastuzumab-Dttb) · HCPCS Q5112

2024 spending

$19.0M

Beneficiaries

1,844

12,594 claims

Per beneficiary

$10,291

2024 ASP limit $34.90 per unit

View as table
YearSpending
2020$552,290
2021$11,340,522
2022$31,856,450
2023$35,649,012
2024$18,977,486

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,879 on PubMed

Sponsor: Samsung Bioepis CO LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.